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Abstract: 
The long saphenous vein is the most commonly used conduit in coronary artery bypass graft 
(CABG) surgery when bypassing multiple diseased arteries; however, its use is complicated by the 
development of vascular inflammation, intimal hyperplasia and accelerated atherosclerosis leading 
to compromised graft efficacy. Despite refinement of surgical techniques to improve graft patency 
late vein graft failure remains a significant problem. Moreover, there is a lack of pharmacological 
interventions proven to be effective in the treatment of late vein graft failure. A greater 
understanding of the molecular nature of the disease and the interactions between endothelial and 
smooth muscle cells as a result of alterations in local haemodynamics may assist with designing 
future beneficial pharmacological interventions. 
Venous endothelial cells (ECs) are physiologically adapted to chronic low shear stress; however, 
once the graft is implanted into the arterial circulation, they become suddenly exposed to acute high 
levels of shear stress. A small number of in vitro and ex vivo studies have demonstrated that acute 
high shear stress is associated with the activation of a pro-inflammatory profile in saphenous vein 
ECs, which may be mediated by mitogen-activated protein kinase (MAPK) and nuclear factor-B 
(NF-B) signalling pathways. The impact of acute changes in shear stress on venous ECs and the 
role of ECs in the development of intimal hyperplasia remains incomplete and is the subject of this 
review. 
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1. Introduction: 
Ischaemic heart disease (IHD) is a leading cause of morbidity and mortality in the Western world 
[1]. It occurs as a result of mismatch in oxygen demand and supply usually due to atherosclerosis in 
one or more of the coronary arteries leading to significant stenosis in the coronary circulation. 
Management of IHD can be non-invasive, through modulating risk factors and using 
pharmacological agents, or invasive, including percutaneous coronary intervention (PCI) and/or 
coronary artery bypass grafting (CABG), aimed towards unblocking or bypassing the occlusion, 
respectively [2,3]. CABG remains the gold standard intervention in many patients in the presence of 
complex coronary disease, diabetes and poor ventricular function [4-7].  
The long saphenous vein (LSV) is commonly used as a conduit for CABG in patients with multi-
vessel coronary artery disease because it is easy and quick to harvest and it can also provide enough 
length to bypass multiple diseased coronaries [5,6,8]. The left internal mammary artery (LIMA) to 
left anterior descending coronary artery (LAD) is the graft of choice for patients receiving a single 
graft due to its higher long-term patency compared with LSV and improved long-term survival 
benefit [9,10]. The use of LIMA is, however, restricted to a single graft primarily, though occasionally 
can be used to sequentially graft another neighbouring coronary vessel as well. Alternatively, 
patients requiring multiple grafts may receive IMA in conjunction with the radial artery or another 
arterial graft such as the right internal mammary [11,12]. However, the utilisation of multiple arterial 
grafting in CABG remains low in general [13,14]. Whereas, for patients with multi-vessel coronary 
artery disease, at least one or more LSV graft will still be used and the LSV remains an important 
conduit in CABG. The use of LSV is not without limitations; its longevity continues to be 
complicated by the development of vascular inflammation, intimal hyperplasia (IH) and accelerated 
atherosclerosis leading to compromised graft efficacy and ultimately, graft failure [15].  
Vein graft failure (VGF) can be separated into two distinct temporal categories; firstly, early graft 
failure can be defined as that which has been reported within one-year post-implantation and it 
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occurs in 3-15% of venous grafts. However, early graft failure is most commonly due to technical 
mismanagement leading to thromboses which may cause the vessel to become occluded. Whereas, 
late stage graft failure is characterised by the prolonged development of superimposed 
atherosclerosis on the vessel wall; by contrast, this late stage VGF occurs in approximately 50-60% 
of grafts within 10 years (Figure 1) [16]. Many cellular processes occur within the graft that can 
trigger the development of IH; these are initiated by both pre- and post-implantation injury of the 
vessel wall. Initially, migration of vascular smooth muscle cells (VSMCs) from the medial to 
intimal layer due to phenotypic switching from contractile to synthetic state occurs [17,18]. Increased 
levels and activation of matrix-degrading metalloproteinases (MMPs) facilitate VSMC migration 
through remodelling of the extracellular matrix (ECM) [19]. Once within the intima, VSMCs 
proliferate, which, when accompanied with increased ECM deposition (collagen and proteoglycans, 
but not elastin), initiates the narrowing and stiffening of the bypass graft (Figure. 2) [20,21].  
Surgical advances in CABG have led to the great increases in patency rates of LSV grafts with the 
introduction of practices such as low-pressure vessel distension and the use of the ‘no-touch’ 
technique, whereby, during harvest of the LSV, the perivascular fat surrounding the vessel is 
preserved [22]. Of particular growing interest, is the role that preservation of perivascular adipose 
tissue (PVAT) plays in the pathophysiology of the vein graft. PVAT has long been overlooked in 
vascular biology, far from being simply an energy source, PVAT releases and receives a number of 
functional substances known to influence vessel behaviour, with functions as diverse as relaxation 
to inflammation [23]. It is well recognised that the use of the ‘no-touch’ technique results in greater 
preservation of the endothelium following harvest; however, what is less well documented is the 
function that remaining PVAT has in maintaining VSMC quiescence and contraction [24]. The 
refinement of LSV surgical harvest techniques has enabled a reduction in conduit damage prior to 
implantation; however, despite efficacy of surgical advancements, very few pharmacological 
studies have been able to improve long-term vein graft patency [25-28]. A greater understanding of 
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the disease pathophysiology, in particular, identifying the immediate changes following 
implantation is necessary to enable improved vein graft patency in the future.  
 
2. The role of ECs in vascular homeostasis 
ECs play a pivotal role in regulating vascular homeostasis, with the quiescent endothelium 
protecting arteries through the promotion of an anti-coagulant and anti-inflammatory environment, 
as well as regulating lipoprotein permeability [29]. Redox balance is extremely important in the 
maintenance of normal functionality in the endothelium [30]. The bioavailability of endothelium 
derived relaxing factors, nitric oxide (NO) and prostaglandin (PGI2), is fundamental to the 
maintenance of vascular tone, as well as the regulation of EC quiescence and VSMC proliferation, 
migration and contractility (Figure. 3a) [31].  The dysregulation of NO balance has profound effects 
for the vascular wall, particularly in the context of the vein graft, with the tipping of this balance to 
reduced NO availability and increased ROS production, in particular, superoxide (O2
.-) generation, 
primarily through eNOS uncoupling by combined actions of NADPH oxidase (NOX) and arginase 
enzymes [30,32-34]. Increased superoxide generation is common in a number of vascular pathologies, 
functioning to scavenge NO (together form peroxynitrite (ONOO-) and directly regulating VSMC 
proliferation, which begins the development of a highly atherogenic environment initiated by 
endothelial dysfunction [35]. Similarly, the two transcription factors, lung Kruppel-like factor 2 
(KLF2) and Nuclear factor erythroid 2-related factor (Nrf2), which target a myriad of genes 
involved in the antioxidant and cellular defence responses, in particular, eNOS and heme-
oxygenase-1 (HO-1), are  of paramount importance in maintenance of redox balance are [36]. 
Once activated, ECs initiate complex networks of adhesion molecules, cytokines and recruitment 
of inflammatory cells, which act to disseminate physiological changes within the endothelium itself 
and the vascular wall through interactions with VSMCs and ECM [37]. Vasospasm, surgical trauma, 
and ischaemia during the harvesting of the conduit typically result in EC activation [38,39]. It has 
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been reported that the surgical trauma during vein harvest can lead to the induction of pro-
inflammatory signalling pathways and EC activation and loss, which can be greatly prevented by 
the utilization of minimum or no touch techniques during the harvest process [40-42]. ECs are further 
activated by the sudden exposure to new mechanical forces in the arterial circulation, including 
distension and increased shear stress [43,44].   
EC activation results in the triggering of the ‘adhesion cascade’ characterised by the rapid 
expression of chemokines such as monocyte chemotactic protein 1 (MCP-1)) and the expression of 
adhesion molecules, including those of the Selectin family (E-Selectin and P-Selectin) and the 
cellular adhesion molecule family, intercellular adhesion molecule 1 (ICAM1), platelet endothelial 
cell adhesion molecule 1 (PECAM1) and vascular cell adhesion molecule 1 (VCAM1) [45,46]. Initial 
activation of the endothelium rapidly leads to leukocyte recruitment, which is in part mediated 
through changes in calcium (Ca2+) homeostasis and the Ras homologue (RHO) pathway (Figure. 
3b) [47,48]. Activation of the RHO pathway through ligand binding to G-Protein coupled receptors 
(GPCRs) functions to loosen tight junctions between endothelial cells and activate GTPases, 
whereas increases in intracellular Ca2+ facilitates the movement of P-Selectin to the luminal surface 
[49]. Together, these rapid actions of GPCRs and Ca2+ help to facilitate leukocyte trans-endothelial 
migration [50]. However, the actions of transduction through RHO and Ca2+ are fleeting and GPCRs 
quickly become desensitised (approximately 10 minutes post-stimulus); as such, this phase of acute 
inflammation is commonly known as type I [51]. Prolonged inflammatory activation of ECs requires 
the sustained action of physiologic stress- or cytokine-mediated signalling through the involvement 
of mitogen activated protein kinases (MAPKs) and pro-inflammatory transcription factors nuclear 
factor kappa B (NF-κB) and activating protein 1 (AP-1) [52-54]. Typically, NF-κB and MAPK 
mediated inflammatory responses involve the comparable, but not exclusive, expression of many 
genes associated with the adhesion cascade, cytokines, chemokines and MMPs in a time-dependent 
and evolving manner between 10 minutes and 24 hours after activation (Figure 3c) [55,56]. Having 
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such integral roles in the propagation of inflammatory responses makes these pathways exciting 
therapeutic targets for the treatment of many vascular pathologies and other systemic disorders 
involving inflammation.  
 
3. CABG conduit comparison 
LSV and IMA differ vastly in structure and functional capability. The IMA is structurally a very 
elastic artery with a medial layer formed of distinct sheets of interspersed wave-like collagen and 
VSMCs arranged circumferentially with very little variability under arterial pressure [57]. 
Interestingly, the IMA shares a great deal of structural homology with the LAD, the primary 
differences being that it possesses a smaller VSMC medial area and more elastin [58]. Whereas the 
LSV is considerably more varied in size and structure, with a much narrower medial layer composed 
of primarily collagen, fenestrated elastic laminae, less elastin and fewer VSMCs [57]. Thus, the LSV 
suffers from ‘compliance mismatch’ under higher physiologic pressures in the arterial circulation 
than is typical in the venous circulation, whereby the vessel is unable to passively expand to 
accommodate the higher pressure due to its inherently thinner, less dense medial layer and its highly 
aligned collagen [59]. Furthermore, arterial and venous vascular beds emanate from molecularly 
distinct foundations and exhibit early differences in signalling pathways including ephrin 
B2/EphB4, VEGF-A and Notch which define vessel identity before initiation of circulatory flow 
[60].  
Within mature blood vessels, the endothelium is typically continuous and non-fenestrated, with 
each cell within the monolayer being attached through intercellular tight or adherens junctions [61]. 
Arterial ECs (aECs) exhibit many more tight junctions per cell than venous ECs (vECs), owing to 
the considerably higher pressure within the arterial system [62]. Greater tight junction distribution in 
aECs function to prevent para-cellular transport, thus reducing endothelial permeability to solutes 
and lipids [63]. Moreover, different haemodynamic patterns between the arterial and venous tree 
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result in aECs alignment with the direction of flow and they become elongated and flattened, 
whereas vECs do not align with flow and are morphologically shorter and wider [64] (Figure. 3). 
Interestingly; such morphological patterns can be reversible both in vivo and in vitro [65] suggesting 
that EC phenotypes maintain a degree of plasticity. This adaptability is particularly evident in vitro, 
with the loss and gain of numerous expressed genes characteristic of EC type (or location) once 
cells have been passaged, clearly showing the impact of cellular microenvironment on EC 
phenotype [66].  
When comparing the impact of altered haemodynamics (mainly shear stress), we noted that vECs 
respond to acute changes in shear stress by inducing a pro-inflammatory profile mediated by the 
activation of MAPK signalling pathway, while aECs remained resistant to such stimuli [67]. This 
differential response is related the fact that aECs react to shear stress by upregulating anti-
inflammatory mediators such as MKP-1 and NRF-2, and this response appears to be innately 
reduced in vEC [68,69].  
 
 
4. Intimal hyperplasia and the endothelium 
IH is the result of chronic structural changes occurring in vein grafts due to abnormal migration and 
proliferation of VSMCs accompanied by an increase in the amount of ECM [18,38,70].  The role of 
ECs in the development of IH has not yet been fully elucidated; previous studies have suggested 
that ECs may not be important as they are lost following surgery [71]. Although, most of these studies 
observed late time points and did not address the immediate changes in ECs. Moreover, it has not 
been determined whether EC denudation and loss is purely mechanical or is driven by EC activation 
and apoptosis in response to acute changes in unconditioned ECs. It is widely accepted that 
harvesting and implantation of LSV impacts on EC integrity to some degree [72], though recent 
studies using improved surgical resection suggest that the endothelium is better preserved following 
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surgery [73,74]. However, these studies fail to address the degree of dysfunction in the preserved 
endothelium. In fact, studies using an ex vivo perfusion model of LSV demonstrated that vECs are 
preserved but activated in response to acute shear stress [35,37]. We have corroborated these findings 
by demonstrating that acute exposure of LSV to high shear stress is associated with minimum 
denudation and significant pro-inflammatory response in vECs [75,76].Our understanding of the role 
of inflammatory pathways, in particular MAPKs and NF-κB, in relation to vein graft disease and 
their mode of regulation remains limited. In a canine model of external jugular vein interposition 
in the carotid artery, it was suggested that MAPK pathway activation is bimodal, as p38 activation 
was noted rapidly (between 30 min and 3 h) after surgery and later (4 days), which, at a later time-
point, was associated with VSMC activation [77]. Topical MAPK inhibitors significantly suppressed 
graft disease in a rabbit inter-positional model of vein grafting [78], although not cell-specific, this 
provides further evidence for the role of MAPK in vein graft failure. Moreover, pharmacological 
vasorelaxation suppressed p38 activity and restricted the activation of proliferation and cell cycle 
progression in the porcine carotid jugular interposition graft [79]. Further evidence for the inhibition 
of inflammatory processes in vein graft disease is scarce. However, in a rabbit model for IH, site-
specific delivery of an NF-κB decoy was shown to significantly suppress neointimal formation 
[80,81]. Taken together, these studies suggest a potentially unexplored role for the therapeutic use of 
anti-inflammatory compounds in the treatment of VGF. 
 
4.1. Shear stress and IH 
Blood vessels are influenced by several forces relating to fluid dynamics (shear stress and 
hydrostatic pressure) and wall mechanics (traction, and distension) [82,83]. Shear stress, which is the 
tangential frictional force acting longitudinally on the vessel wall imposed by fluid motion on a 
solid boundary parallel to the fluid direction [36], is one of the most important forces that directly 
regulates EC physiology and vascular inflammation. 
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There is a significant increase in wall shear stress immediately after implanting LSV into arterial 
circulation [84] leading to rapid cytoskeletal remodelling and activation of multiple signalling 
cascades in ECs [85]. The exposure of ECs to high shear stress can result in the rapid activation of 
Ras (>1 min) which is followed by an increase in the activities of extracellular-signal regulated 
kinase (ERK) (10 min) and c-Jun N-terminal kinase (JNK) (30 min) [86]. ERK activation may lead 
to c-fos gene expression and JNK activation may induce c-Jun phosphorylation which acts to 
increase AP-1/TPA response element (TRE) transcriptional activity [87]. Furthermore, acute sudden 
increases in shear stress result in the early development of inflammation, demonstrated by the 
expression of MCP-1 and infiltration of monocytes; thus seeding the environment for atherogenesis 
[88]. Inflammatory cells and adhesion cascades are in fact so inextricably linked to vein graft intimal 
hyperplasia development that depletion of macrophages or knock-down of ICAM-1 has been shown 
to significantly reduce rates of vein graft disease [89,90]. In vitro studies using human umbilical vein 
ECs (HUVECs) showed that acute exposure to high shear stress can lead to early activation of 
ERK1/2 and p38 [91,92]. Furthermore, we have demonstrated that in vitro and ex vivo exposure of 
vECs to acute shear stress is associated with the activation of p38; this was in turn associated with 
increased MCP-1 production. Suppression of p38 activity can also lead to significant reduction in 
pro-inflammatory responses to acute shear stress [71].  
Acute shear stress appears to activate NF-κB in an integrin dependent manner. Once integrins are 
activated, they are able to begin inducing signals which include activation of small GTPase, RhoA 
and Rac1 [93]. In turn, Rac1 induces NADPH oxidase to produce ROS, functioning to stimulate the 
critical NF-κB kinases, I-kappa B kinase beta (IKKβ) and NF-κB inducing kinase (NIK), which 
together trigger classical activation of the NF-κB pathway [94,95]. Activation of the NF-κB pathway 
by shear stress is most likely not as singular or simple as has been suggested, however. There are 
other elements involved for ultimate transcriptional activation, many of which perhaps remain 
unidentified. For example, focal adhesion kinase (FAK), a crucial member of the integrin-
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dependent shear stress induced EC activation mechanism, does not explicitly stimulate NF-κB 
translocation but rather, is responsible for phosphorylation of the transcription factor, which is 
intimately linked to the transcriptional activity of NF-κB [96]. Whereas p21-activated kinase (PAK), 
which is flow dependent, also functions as a crucial element in the oxidant dependent activation 
NF-κB through NIK, though, unlike Rac1, has absolutely no effect on ROS production [93].  
Taken together, these studies of the flow induced activation of the endothelium describe a relatively 
confusing picture, particularly in the context of the vein graft. Nevertheless, focal inhibition of acute 
shear stress mediated induction of NF-κB and MAPK pathways represent an exciting therapeutic 
direction in the treatment of vein graft disease. 
 
5. Current clinical pharmacological strategies  
Developments of pharmacologic interventions for the treatment of VGF continue to endeavour in 
pursuit of a suitable therapeutic target for both cellular specificity and efficacy. Secondary 
prevention of the symptoms of late VGF pharmacologically provides equally demanding questions 
relating to treatment strategy. Addressing maintenance of EC functionality after surgical trauma is 
of paramount importance both pre- and peri-operatively for SVGs; this requires preservation of 
endothelial coverage, as well as preservation of the vasomotor actions of ECs (reviewed in detail 
elsewhere [97]). Recent developments have led to the renewed interest in the pleiotropic effects of 
statins for preservation of EC function, due to their role in the conservation of redox balance in the 
endothelium and vascular wall [98]. In addition to the widely understood lipid-lowering effects of 
statins, it has been reported that they are able to prevent activation of pro-oxidant systems whilst 
boosting cellular defence mechanisms. Pre-treatment of CABG patients with Atorvastatin improved 
redox balance in patients after surgery, as well as in an ex vivo SVG model, shown by reduced 
plasma levels of monodialdehyde, a marker of oxidative stress, and inhibition of NOX activity 
respectively [99]. Antoniades and colleagues further showed that Atorvastatin ameliorates vascular 
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redox state through eNOS coupling in the presence of its co-factor, BH4, ultimately leading to 
reduced vascular superoxide production and improved vessel function [100]. Furthermore, it is well 
understood that Aspirin has a profound impact on reduction of early graft failure by prevention of 
thrombotic events due to its antiplatelet activity; however, Aspirin alone does not appear to have 
much impact on longer-term graft patency [72]. 
In addition to more well-established treatments, the potential for gene therapy in VGF offers an 
interesting therapeutic direction. Intraoperatively, the saphenous vein is easily accessible, allowing 
in situ delivery of gene therapies directly to the tissue [72,76]. However, to date, only one randomised 
controlled trial has assessed gene therapy; the PREVENT-IV study [27]. The trial involved the use 
of a decoy oligonucleotide, edifoligide, which binds to the transcription factor, E2F, known to have 
a role in the initiation of IH. Edifoligide appeared to have no benefit in preventing VGF at between 
12 and 18 months post-surgery and the trial failed at stage IV [27]. Despite certain advances in the 
development of pharmacologic agents for the acute treatment of VGF, the longer-term benefits of 
many of these studies are yet to be demonstrated in their extension of vein graft viability.  
 
6. Conclusions 
The use of LSV as conduit in surgery is complicated by the development of vein graft disease 
leading to vein stenosis. The role of vECs in the development of IH and accelerated atherosclerosis 
is not yet fully elucidated. The implantation of LSV into arterial circulation can lead to the 
activation of vECs in response to acute exposure to high shear stress and the activation of different 
pro-inflammatory cascades. However, the limited amount of available data suggests that acute 
increases shear stress in the vein graft may be associated with the activation of MAPK and NF-B 
signalling pathways, which may result in vEC apoptosis and loss (Figure 4). Suppression of acute 
activation of the venous endothelium represents a largely unexplored possibility in the treatment of 
14 
 
vein graft disease and may provide the potential to improve graft patency both in the short and 
longer term. 
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Figure. 1. Early vs Late stage vein graft failure. Early graft failure primarily occurs due to 
technical problems during surgery causing significant damage to the endothelium which 
ultimately result in thrombosis. Late stage graft failure is a much slower process leading to 
development of superimposed atherosclerosis on the vein graft wall. EC: endothelial cell; ROS: 
reactive oxygen species; ECM: extracellular matrix; VSMC: vascular smooth muscle cell; SS: 
shear stress; 10m: 10 minutes; 2wks: 2 weeks; 1 yr: 1 year. 
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Figure 2. Mechanism of intimal hyperplasia. Temporal development of late stage vein graft 
failure beginning from surgical trauma and altered haemodynamics, ultimately leading to 
intimal thickening and vascular remodelling through the combined actions of multiple 
vascular cell types and extracellular matrix interactions. EC: endothelial cell; ECM: 
extracellular matrix; VSMC: vascular smooth muscle cell; IEL: internal elastic lamina; EEL: 
external elastic lamina.  
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Figure. 3. Endothelial cell inflammatory response. The endothelium is the first point of contact 
for systemic sources of inflammation; as such, it’s response is hugely important in propogation 
of inflammatory stimuli through the vessel wall and beyond. (A) Within the quiescent venous 
endothelium (i.e. in veins with normal flow without venous reflux, venous insufficiency or 
stasis), ECs upregulate levels of KLF2 and Nrf2 dependent genes, including eNOS and HO-1, 
and secrete gasotransmitters NO and PGI2. (B) Upon insult of acute high shear stress following 
immediate implantation into the arterial circulation, vECs activate the Rho-GTPase pathway 
which affects downstream effectors and the cytoskeleton. Within the first 10 minutes of acute 
high flow there is also an increase in intracellular calcium leading to movement of P-Selectin 
to the luminal surface. Together these actions constitute type I (acute) inflammation. (C) 
Following this, there is activation of a more prolonged (type II) inflammatory response, which 
results in the activation of MAPK mediated and NF-κB pro-inflammatory pathways; resulting 
in expression of adhesion molecules, cytokines, chemokines and increases in intracellular ROS. 
The interplay between ECs and VSMCs acutely in the vein graft remains unclear with the 
extent of intercellular communication a relatively unexplored area. PI3K: Phosphatidylinositol-
4,5-bisphosphate 3-kinase; Akt: Protein kinase B; PKA: Protein kinase A; AMPK: adenosine 
monophosphate-activated protein kinase; ERK5: Extracellular-signal-regulated kinase 5; 
HMOX-1: heme-oxygenase 1; NQO-1: NADPH-dehydrogenase 1; GCLM: Glutamate-
cysteine ligase regulatory subunit; Nrf2:  Nuclear factor erythroid 2-related factor 2; NOS3: 
endothelial nitric oxide synthase; LSS/PSS: Laminar or pulsatile shear stress; ASS1: 
Argininosuccinate synthetase; CNP: C-natriuretic peptide; KLF2: lung-Kruppel-like factor 2; 
NO: Nitric oxide; PGI2: Prostaglandin; EC: endothelial cell; SREBP: Sterol regulatory 
element-binding protein; MAPK: Mitogen activated protein kinase; Ca2+: Calcium; VSMC: 
Vascular smooth muscle cell; JNK: c-Jun N-terminal kinases; p38: P38 mitogen-activated 
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protein kinases; PKCζ: Protein kinase C, zeta; AHSS: Acute high shear stress; AP-1: activating 
protein 1; ROS: Reactive oxygen species; IKK: IκB kinase complex; IκBα: Nuclear factor of 
kappa light polypeptide gene enhancer in B-cells inhibitor, alpha; p50/p65: Nuclear factor 
kappa-light-chain-enhancer of activated B cells (50 and 65kDa heterodimeric subunits); MCP-
1: Monocyte chemotactic protein 1; IL-8: Interleukin 8; VCAM-1: Vascular cell adhesion 
protein 1; MMPs: Matrix metalloproteinases; PDGF-BB: Platelet-derived growth factor 
subunit B homodimer; TGF-β: Transforming growth factor beta; KLF4: Kruppel-like factor 4; 
COXII: Cyclooxygenase 2. 
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Figure. 4. Proposed mechanism of the impact of acute high shear on vECs. Acute high shear 
leads to activation of signalling pathways such as NF-B and MAPK in vECs, leading to up-
regulation of pro-inflammatory genes and resultant phenotype changes in VSMC which cause 
the development of IH. NF-B: Nuclear factor kappa-light-chain-enhancer of activated B cells; 
p38: P38 mitogen-activated protein kinases; EC: Endothelial cell; SMC: Vascular smooth 
muscle cell. 
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